首页 > 期刊杂志 > 正文

The LAST Guidelines in Clinical Practice: Implementing Recommendations for p16 Use.

临床实践LAST指南:推荐使用p16

Clinton LK,Miyazaki K,Ayabe A,Davis J,Tauchi-Nishi P,Shimizu D

Abstract

To determine the impact of implementing p16 Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions (LAST) guidelines, we compared p16 use and follow-up data before and after implementation of the guidelines.
We reviewed all cervical biopsy specimens diagnosed by two pathologists before and after implementation of the LAST guidelines and calculated the rate of and reason for p16 use across all biopsy specimens, high-grade squamous intraepithelial lesion (HSIL) detection, and follow-up.
In total, 1,829 and 1,623 cervical biopsy specimens were reviewed in periods A and B, respectively. Overall p16 use increased from 2.8% to 6.2% (P < .001). Recommendations 2 and 4 increased from 0.16% and 0% of all cervical biopsy specimens in period A to 1.4% and 1.9% in period B, respectively (P < .0001). p16+ HSIL increased from 1.4% to 2.3% (P < .05). The positive predictive value of p16+ HSIL increased from 48% to 76% (P < .05).
Implementation of the p16 LAST guidelines resulted in a significant increase in p16 use and a significant increase in the positive predictive value of p16+ HSIL.

摘要

为了确定LAST(Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions)指南中应用p16的影响,我们比较了使用该指南前后p16的使用及随访数据。我们回顾了在使用LAST指南前后由两位病理医师诊断的所有宫颈活检样本,计算并记录所有活检样本中p16的使用、高级别上皮内病变(HSIL)的检出以及随访的比率和原因。总体而言,回顾的A时期和B时期的宫颈活检样本分别为1829例和1623例。p16总的使用比率从2.8%增长到6.2%(P<0.001)。在所有的宫颈活检样本中,推荐使用的2和4分别从A时期的0.16%和0%增长到B时期的1.4%和1.9%(P < 0.0001)。p16阳性的HSIL从1.4%增长到2.3%(P <0 .05)。p16阳性HSIL的阳性预测值从48%增长到76%(P <0 .05)。LAST指南中致使p16的使用以及p16阳性HSIL的阳性预测值显著增加。


full text

我要评论

0条评论